Home Cart Sign in  
Chemical Structure| 1648843-04-2 Chemical Structure| 1648843-04-2

Structure of SX-682
CAS No.: 1648843-04-2

Chemical Structure| 1648843-04-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SX-682

CAS No. :1648843-04-2
Formula : C19H14BF4N3O4S
M.W : 467.20
SMILES Code : OB(C1=CC=C(OC(F)(F)F)C=C1CSC2=NC=C(C(NC3=CC=C(F)C=C3)=O)C=N2)O
MDL No. :MFCD28502254
InChI Key :SDUDZBCEHIZMFZ-UHFFFAOYSA-N
Pubchem ID :90467234

Safety of SX-682

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of SX-682

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
LLC cells 1 μM 24 hours Evaluate the effect of SX-682 on tumor cell apoptosis, results showed SX-682 did not induce apoptosis in LLC cells PMC6483637
MOC1 cells 1 μM 24 hours Evaluate the effect of SX-682 on tumor cell apoptosis, results showed SX-682 did not induce apoptosis in MOC1 cells PMC6483637
B16F10 cells 5 μM 4 days To evaluate the effect of SX-682 on the growth of B16F10 cells, results showed that SX-682 treatment significantly reduced the percentage of Ki-67 positive cells. PMC10239119
B16F0 cells 5 μM 4 days To evaluate the effect of SX-682 on the growth of B16F0 cells, results showed that SX-682 treatment significantly reduced the percentage of Ki-67 positive cells. PMC10239119
Melan-A cells 5 μM 4 days To evaluate the effect of SX-682 on the growth of Melan-A cells, results showed that SX-682 treatment significantly reduced the percentage of Ki-67 positive cells. PMC10239119
UM-SCC-74B 10 µM 72 hours Evaluate the effect of SX-682 on docetaxel sensitivity, results showed IC50 decreased from 0.26 ng/mL to 0.06 ng/mL PMC11619435
UM-SCC-22B 10 µM 72 hours Evaluate the effect of SX-682 on docetaxel sensitivity, results showed IC50 decreased from 0.25 ng/mL to 0.02 ng/mL PMC11619435
UM-SCC-11B 10 µM 72 hours Evaluate the effect of SX-682 on docetaxel sensitivity, results showed IC50 decreased from 0.12 ng/mL to 0.01 ng/mL PMC11619435
LLC cells 5 μM Evaluate the effect of SX-682 on tumor cell viability and proliferation, results showed SX-682 did not alter LLC cell viability or proliferation PMC6483637
MOC1 cells 5 μM Evaluate the effect of SX-682 on tumor cell viability and proliferation, results showed SX-682 did not alter MOC1 cell viability or proliferation PMC6483637

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice MOC2 tumor model Oral 500 mg/kg Once daily for one week SX-682 significantly decreased PMN-MDSC trafficking into MOC2 tumors and enhanced the tumor infiltration, activation, and therapeutic efficacy of adoptively transferred NK cells. PMC7073293
C57BL/6 mice Rich1.1 melanoma model Oral 0.756 g/kg 3 weeks To assess the effect of SX-682 on metastatic tumor progression in vivo, results showed that SX-682 inhibited tumor growth, reduced intratumoral MDSCs, and increased intratumoral B1b cells expressing CXCL11, leading to an increase in activated CD8+ T cells in the tumor. PMC7864868
Mice Ptenfl/fl/Lkb1fl/fl (PL) Mice model of lung squamous cell cancer Oral 500 mg/kg Once daily for 4 weeks To evaluate the effect of SX-682 in combination with anti-PD1 antibody on tumor burden and immune cell infiltration. Results showed that the combination treatment significantly reduced tumor burden and increased CD8+ T cell infiltration into malignant tumor. PMC6975266

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.14mL

0.43mL

0.21mL

10.70mL

2.14mL

1.07mL

21.40mL

4.28mL

2.14mL

References

 

Historical Records

Categories